Interactions between thrombophilic genetic mutations and clinical bleeding in patients on chronic oral anticoagulant treatment.

Abstract

We studied the prevalence of genetic thrombophilic mutations in patients on chronic oral anticoagulant treatment (OAT) who had bleeding complications. In a case-control study we found ten (12.8%) carriers of factor V Leiden and two (2.5%) carriers of the PT20210A mutation among 78 patients with a history of moderate-severe bleeding while on OAT, and seven (4.4%) and four (2.5%), respectively, among 156 matched patients with no bleeding while on OAT (odds ratio 3.1+/-1.6, p=0.026). In patients on chronic OAT, FV Leiden is a risk factor for moderate-severe bleeding.

• Authors: Luigi Castori, Maria Rita Taliani, Giancarlo Agnelli, Enrico Boschetti, Paolo Gresele
• Journal: Haematologica (Haematologica) Vol. 90 Issue 12 Pg. 1720-2 (Dec 2005) ISSN: 1592-8721 [Electronic] Italy
• PMID: 16330459 (Publication Type: Letter)

Chemical References

• 3' Untranslated Regions
• Anticoagulants
• factor V Leiden
• Warfarin
• Factor V
• Prothrombin
• Acenocoumarol

Topics

• 3' Untranslated Regions
• Acenocoumarol (administration & dosage, adverse effects)
• Administration, Oral
• Aged
• Aged, 80 and over
• Anticoagulants (administration & dosage, adverse effects)
• Case-Control Studies
• Factor V (analysis, genetics)
• Female
• Follow-Up Studies
• Gene Frequency
• Hemorrhage (chemically induced, genetics)
• Hospitalization (statistics & numerical data)
• Humans
• International Normalized Ratio
• Male
• Middle Aged
• Prevalence
• Prothrombin (genetics)
• Sample Size
• Thrombophilia (epidemiology, genetics)
• Warfarin (administration & dosage, adverse effects)